CoChat

Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus

Open access
Wring, Stephen, Murphy, Gail, Atiee, George, Corr, Christy, Hyman, Michele, Willett, Michael, Angulo, David · 2019 · Clinical Pharmacology in Drug Development
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

SCY‐078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species. This was a sequential, single‐center, open‐label phase 1 study to assess the drug‐drug interaction potential between SCY‐078 and tacrolimus during concomitant administration in healthy subjects. In cohort 1, period 1, subjects received a single oral dose of tacrolimus 2 mg in the fasted state. In period 2 after a ≥15 day washout, subjects received a single loading dose of SCY‐078 1250 mg on day 1 followed by maintenance doses of SCY‐780 750 mg on days 2 through 8. On day 3 of period 2, subjects also received a single dose of tacrolimus 2 mg concurrent with SCY‐078. In cohort 2, subjects received a loading dose of SCY‐078 1250 mg on day 1 followed by maintenance doses of SCY‐780 750 mg on days 2 and 3. Pharmacokinetic (PK) parameters were compared to assess both the impact of steady‐state SCY‐078 on tacrolimus and the impact of tacrolimus on the PK of steady‐state SCY‐078. The concurrent coadministration of tacrolimus and SCY‐078 had no effect on the maximum blood levels of tacrolimus, as evidenced by no change in maximum concentration of drug in blood plasma and a 1.4‐fold increase in total area under the plasma drug concentration–time curve. The concurrent coadministration of tacrolimus and SCY‐078 resulted in a weaker interaction than typically observed with the azole class of antifungals. The current data indicate that an initial dose adjustment for tacrolimus may not be warranted when combined with SCY‐078, as the modest increase in exposure is less than the therapeutic window, although tacrolimus monitoring, as with addition of any new medication, is recommended. These results support the coadministration of SCY‐078 and tacrolimus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cpdd.588

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Wring, S., Murphy, G., Atiee, G., Corr, C., Hyman, M., Willett, M., & Angulo, D.
Venue
Clinical Pharmacology in Drug Development
Publisher
Wiley
Published
2018-06-27
Volume
8
Issue
1
Pages
60-69
ISSN
  • 2160-763X (ISSN-L)
  • 2160-7648
OpenAlex
W2809686644
Cited by
45
References
2
FWCI
3.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.